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of Interstitial Lung Disease with Lung Cancer
Hirotsugu Kenmotsu, MD,* Tateaki Naito, MD,* Madoka Kimura, MD,* Akira Ono, MD,*
Takehito Shukuya, MD,* Yukiko Nakamura, MD,* Asuka Tsuya, MD,* Kyoichi Kaira, MD,*
Haruyasu Murakami, MD,* Toshiaki Takahashi, MD,* Masahiro Endo, MD,†
and Nobuyuki Yamamoto, MD*
Introduction: It is unknown what type of interstitial lung disease
(ILD) has high risk for chemotherapy-related exacerbation of ILD.
We investigated the risk of exacerbation of ILD for patients with
lung cancer with ILD.
Methods: One hundred nine patients with lung cancer with ILD
treated with cytotoxic chemotherapy at Shizuoka Cancer Center
between August 2002 and April 2010 were retrospectively reviewed.
Results: On pretreatment computed tomography (CT) of the chest,
69 patients (63%) were identified with usual interstitial pneumonia
(UIP) pattern, and 40 patients (37%) had non-UIP pattern. Patients
with UIP pattern developed cytotoxic chemotherapy-related exacer-
bation of ILD more frequently than those with non-UIP pattern (30
versus 8%, p  0.005). The incidence of grade 5 pulmonary
toxicities was 9% in patients with UIP pattern, compared with 3% in
those with non-UIP pattern. Multivariate analyses demonstrated that
age (70 years) and CT pattern (UIP) were significant independent
risk factors for cytotoxic chemotherapy-related exacerbation of ILD.
In small cell lung cancer, overall survival (OS) from the start of
first-line chemotherapy was significantly shorter in UIP pattern than
non-UIP pattern (median OS: 9 versus 16 months, p  0.0475),
whereas there was no significant difference in patients with non-
small cell lung cancer (median OS: 12 versus 9 months, p 
0.2529).
Conclusions: Our results indicated that the incidence of exacerba-
tion of ILD was significantly higher in patients with lung cancer
with UIP pattern on CT findings than in those with non-UIP pattern.
Therefore, great care is required when administering cytotoxic
chemotherapy agents for patients with lung cancer with UIP pattern.
Key Words: Lung cancer, Interstitial lung disease, Usual interstitial
pneumonia, Cytotoxic chemotherapy, Exacerbation.
(J Thorac Oncol. 2011;6: 1242–1246)
Interstitial lung disease (ILD) is called diffuse parenchymallung disease and is a diverse group of pulmonary disorders
classified together because of similar clinical, radiological,
physiological, or pathological features.1 Preexisting ILD or
idiopathic interstitial pneumonias (IIPs) are considered to be
a risk factor for drug-related ILD.2 A prospective large cohort
study for gefitinib, an epidermal growth factor receptor ty-
rosine kinase inhibitor, has shown that preexisting ILD is not
only a strong risk factor for gefitinib-related ILD but also a
strong risk factor for cytotoxic chemotherapy-related ILD.3
Cytotoxic chemotherapy agents, such as gemcitabine, do-
cetaxel, and amrubicin, have been reported to develop severe
ILD associated with cytotoxic chemotherapy.4–6 Chemother-
apy-related ILD is not common but is a potentially fatal
complication of treatment for lung cancer.
Idiopathic pulmonary fibrosis (IPF) is a chronic pro-
gressive interstitial pneumonia of unknown cause limited to
the lungs and associated with poor prognosis.7,8 The Ameri-
can Thoracic Society (ATS) and European Respiratory Soci-
ety (ERS) have defined IPF as clinical conditions character-
ized by progressive dyspnea and chronic cough, restrictive
lung disease, and the histopathologic pattern of usual inter-
stitial pneumonia (UIP).7 In addition, in patients with IPF, the
incidence of lung cancer is reported to be higher than in
patients without IPF.9–13
In clinical practice, patients with lung cancer with ILD
have been carefully treated with cytotoxic chemotherapy.
Nevertheless, it is unknown what kind of chemotherapeutic
agents are optimal for patients with lung cancer with ILD. In
addition, it is also unknown what type of ILD has high risk
for exacerbation of ILD.
To assess the risk of cytotoxic chemotherapy-related
ILD, we retrospectively analyzed pretreatment computed to-
mography (CT) and investigated the clinical course of pa-
tients with lung cancer with ILD.
METHODS
The medical records of patients with lung cancer with
ILD treated with cytotoxic chemotherapy at the Shizuoka
Cancer Center between August 2002 and April 2010 were
retrospectively reviewed. In this study, pretreatment CT of
the chest was evaluated by one radiologist (M.E.) and two
pulmonologists (H.K. and T.N.), who had no knowledge of
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the patient’s outcome. The chest CT examinations were
performed using multidetector-row CT machine at the end of
suspended inspiration. CT images were reconstructed to
5-mm slice thickness, and thin section chest CT with 1 mm
reconstruction thickness was also performed for evaluating
primary tumor and ILD. ILD was diagnosed when the criteria
of ground-glass opacity, consolidation, or reticular shadow in
both lung fields were met. On the basis of CT characteristics,
we classified the patients with ILD into two groups: UIP
pattern and non-UIP pattern. Diagnosis of UIP pattern was
based on CT features as defined by the International Consen-
sus Statement of the ATS and ERS, showing subpleural
distribution, honeycombing, traction bronchiectasis, and ar-
chitectural distortion (Figure 1A).7,14 All other cases, whose
CT of the chest revealed ILD excluding the UIP pattern, were
diagnosed as non-UIP pattern (Figure 1C).
Chemotherapy-related exacerbation of ILD was diag-
nosed on the basis of CT findings (bilateral ground-glass
abnormality with or without focal consolidation, superim-
posed on pretreatment interstitial shadow) (Figure 1B).15
Patients with apparent pulmonary infection, pulmonary em-
bolism, or heart failure were excluded. Chemotherapy-related
exacerbation of ILD was evaluated based on pneumonitis/
pulmonary infiltrates by National Cancer Institute Common
Terminology Criteria version 3.0—grade 3: symptomatic,
interfering with activities of daily living, and oxygen indi-
cated; grade 4: life-threatening; and grade 5: death. The
patients who developed exacerbation of ILD within 1 year
after thoracic radiotherapy and who received epidermal
growth factor receptor tyrosine kinase inhibitor in the clinical
course were excluded from chemotherapy-related exacerba-
tion of ILD. To assess the incidence of exacerbation of ILD
by treatment regimen, the duration between last administra-
tion of cytotoxic chemotherapy and the onset of exacerbation
of ILD was defined as 4 weeks or less.
Univariate and multivariate analyses were performed to
identify risk factors for the exacerbation of ILD associated
with cytotoxic chemotherapy. All categorical variables were
analyzed by the 2 test or Fisher’s exact test, as appropriate.
Multivariate analyses were performed using a logistic regres-
sion procedure to assess the relationship between various
factors and exacerbation of ILD. Clinical evaluation of over-
all survival (OS) after the start of first-line chemotherapy was
conducted by the Kaplan-Meier method to assess the time to
death. The log-rank test was used to compare cumulative
survival in each group. All p values were reported as two-
sided, and values less than 0.05 were considered statistically
significant. This study was approved by the institutional
review board.
RESULTS
Patient Characteristics
One hundred nine patients were diagnosed with lung
cancer with ILD and treated with cytotoxic chemotherapy.
The characteristics of the patients are shown in Table 1. The
median age was 69 years (range: 54–84 years), and almost all
patients were smokers and men with good performance sta-
tus. Histologically, adenocarcinoma, squamous cell carci-
noma, and small cell lung cancer (SCLC) were observed in
33, 30, and 30%, respectively. Others included large cell
carcinoma and undifferentiated non-small cell cancer. Stages
III and IV were observed in 40 and 53%, respectively, and
recurrence after surgical resection occurred in 7%. In SCLC,
limited and extensive diseases were observed in 33 and 67%,
respectively. On the basis of pretreatment CT of the chest, 69
patients (63%) were identified with UIP pattern, and 40
patients (37%) had non-UIP pattern. Although there were
some imbalances between the two groups in terms of stage IV
FIGURE 1. High-resolution computed tomography (HRCT) image of the chest. A, Pretreatment HRCT image of the chest
showing subpleural distribution, honeycombing, traction bronchiectasis, and architectural distortion (UIP pattern). B, HRCT
image of the chest showing ground-glass abnormality superimposed on pretreatment interstitial shadow (chemotherapy-re-
lated exacerbation of ILD). C, Pretreatment HRCT image of the chest showing patchy ground-glass opacity with reticulation,
traction bronchiectasis, and architectural distortion (non-UIP pattern). UIP, usual interstitial pneumonia; ILD, interstitial lung
disease.
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(p  0.044), there were no significant differences in patient
characteristics between both groups.
Incidence of Cytotoxic Chemotherapy-Related
Exacerbation of ILD
Of the 109 patients with ILD, 24 (22%) developed
cytotoxic chemotherapy-related exacerbation of ILD. In par-
ticular, patients with UIP pattern developed cytotoxic che-
motherapy-related exacerbation of ILD more frequently than
those with non-UIP pattern (30 versus 8%, p  0.005; Table
2). In addition, the incidence of grade 3 or worse pneumoni-
tis/pulmonary infiltrates was significantly higher in patients
with UIP pattern than in patients with non-UIP pattern (29
versus 5%, p  0.003). Almost all of the patients who
developed grade 3 or worse pulmonary toxicities received
corticosteroid therapy. Nevertheless, 9% of the patients with
UIP pattern died because of exacerbation of ILD, whereas 3%
of those with non-UIP pattern died.
The median time from last administration of cytotoxic
chemotherapy to the diagnosis of the exacerbation of ILD
was 17 days (range: 0–25 days). The incidence rate of
exacerbation of ILD is shown in Table 3 for each agent;
docetaxel (28%) or etoposide (24%) frequently led to exac-
erbation of ILD for patients with UIP pattern. On the other
hand, the incidence of exacerbation of ILD was relatively low
for vinorelbine or paclitaxel. Cisplatin or carboplatin was
mainly administered with another agent, and it was difficult
to assess the risk for ILD. In patients with SCLC, 63% of
exacerbation of ILD occurred during the first-line chemother-
apy, whereas in patients with non-small cell lung cancer
(NSCLC) the corresponding proportion was 31%. In addition,
only one patient received further chemotherapy after exacer-
bation of ILD.
The Risk of Cytotoxic Chemotherapy-Related
Exacerbation of ILD
The results of the univariate analysis of risk factors for
cytotoxic chemotherapy-related exacerbation of ILD are
shown in Table 4. UIP pattern on CT was significantly
associated with the exacerbation of ILD (p  0.005). Multi-
variate analyses were performed using three variables (age,
performance status, and CT pattern), and the results demon-
strated that age (70 years) (odds ratio [OR]: 2.75, 95%
confidence interval: 1.03–7.93) and CT pattern (UIP) (OR:
TABLE 2. Incidence of Cytotoxic Chemotherapy-Related
Exacerbation of ILD
No. of Patients (%)
p
Total,
n (%)
UIP Pattern,
n (%)
Non-UIP Pattern,
n (%)
Overall 109 69 40
Exacerbation
of ILD
24 (22) 21 (30) 3 (8) 0.005
 Grade 3 22 (20) 20 (29) 2 (5) 0.003
Grade 3 5 (5) 4 (6) 1 (3)
Grade 4 10 (9) 10 (14) 0
Grade 5 7 (6) 6 (9) 1 (3)
UIP, usual interstitial pneumonia; ILD, interstitial lung disease.
TABLE 3. Cytotoxic Chemotherapy Agents Considered to
Cause the Exacerbation of ILD
UIP Pattern Non-UIP Pattern
No. of
Patients
Administered
Exacerbation
of ILD (%)
No. of
Patients
Administered
Exacerbation
of ILD (%)
Cisplatin 21 2 (10) 21 1 (5)
Carboplatin 40 5 (13) 19 0
Paclitaxel 31 1 (3) 14 0
Docetaxel 25 7 (28) 12 1 (8)
Etoposide 21 5 (24) 10 0
Vinorelbine 13 0 6 0
Gemcitabine 7 3 (43) 10 1 (10)
S-1 7 2 (29) 7 1 (14)
Irinotecan 6 2 (33) 6 0
Amrubicin 4 0 6 0
Pemetrexed 2 1 (50) 1 0
UIP, usual interstitial pneumonia; ILD, interstitial lung disease.
TABLE 1. Patient Characteristics (Overall, n  109)
Total
UIP
Pattern,
n (%)
Non-UIP
Pattern,
n (%) p
No. of patients 109 69 40
Gender 0.117
Male 103 67 (97) 36 (90)
Female 6 2 (3) 4 (10)
Age (yr), median
(range)
69 (54–84) 70 (55–84) 69 (54–80) 0.245
Smoking status 0.763
Never smoker 0 0 0
Ex-smoker 47 29 (42) 18 (45)
Current smoker 62 40 (58) 22 (55)
Performance status
(ECOG)
0.150
0–1 94 62 (90) 32 (80)
2–3 15 7 (10) 8 (20)
Histology 0.723
Adenocarcinoma 36 22 (32) 14 (35)
Squamous cell
carcinoma
33 21 (30) 11 (28)
SCLC 33 20 (29) 13 (32)
Others 8 6 (9) 2 (5)
Clinical stages 0.044
IIIA and B 44 34 (49) 10 (25)
IV 57 31 (45) 26 (65)
Recurrence after surgical
resection
8 4 (6) 4 (10)
SCLC 0.314
Limited disease 11 8 (40) 3 (23)
Extensive disease 22 12 (60) 10 (77)
UIP, usual interstitial pneumonia; SCLC, small cell lung cancer; ECOG, Eastern
Cooperative Oncology Group.
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6.98, 95% confidence interval: 2.04–33.79) were significant
independent risk factors (Table 5).
Overall Survival
In this analysis, the median follow-up duration was
10.3 months. In SCLC, OS from the start of first-line che-
motherapy was significantly shorter in patients with UIP
pattern than those with non-UIP pattern (median OS: 9 versus
16 months, p  0.048), whereas there was no significant
difference in patients with NSCLC (median OS: 11 versus 9
months, p  0.334).
DISCUSSION
In patients with IPF, the incidence of lung cancer is
reported to be higher than in patients without IPF,9–13 and IPF
has been recognized to be an independent risk factor for lung
carcinogenesis.11 There are some reports that patients with
lung cancer with preexisting ILD or pulmonary fibrosis have
a high risk of developing exacerbation after anticancer ther-
apy,3,16–18 and the incidence of exacerbation of ILD was 20 to
24%.16,17 It is very important to establish an optimal treat-
ment, which is considered to be safe and effective, for
patients with lung cancer with ILD or IPF.
To our knowledge, this is the first study to evaluate the
risk of cytotoxic chemotherapy-related ILD based on pre-
treatment chest CT patterns. In clinical practice, patients with
lung cancer with ILD have been carefully treated with cyto-
toxic chemotherapy. Nevertheless, it is unknown what type of
ILD has a high risk for exacerbation of ILD. In this study,
patients with lung cancer with UIP pattern on CT findings
demonstrated a high risk of exacerbation of ILD, compared
with those with non-UIP pattern. This result suggests that
chest CT patterns could be a risk factor for the development
of chemotherapy-related exacerbation of ILD. Although age
(70 years) was also shown to be a risk factor, these patients
might tend to receive multiple drugs for longer periods than
elderly patients.
As there have been few reports about chemotherapy for
patients with lung cancer with ILD, the optimal agent remains
controversial. From Japan, a prospective study to evaluate the
safety and efficacy of weekly paclitaxel in combination with
carboplatin for advanced NSCLC with IIPs was reported.19
One of 18 patients enrolled in this prospective study devel-
oped exacerbation of IIPs. Our study also showed that car-
boplatin and paclitaxel were relatively safe for patients with
lung cancer with ILD, for whom this regimen might be one of
the optimal regimens for those patients. Our results suggested
that vinorelbine might also be relatively safe for patients with
ILD. Nevertheless, we could not completely rule out the
influence of biopsy for lung cancer diagnosis, before chemo-
therapy and before radiotherapy. It is known that the long-
term survival in IPF shows poor prognosis compared with
non-IPF, such as nonspecific interstitial pneumonia and other
subgroups of IIPs.1 In this study, although the UIP pattern on
CT was significantly associated with the exacerbation of ILD,
in patients with NSCLC with UIP pattern OS was not signif-
icantly different from those with non-UIP pattern. On the
other hand, OS was significantly shorter in patients with
SCLC with UIP pattern than in those with non-UIP pattern,
and the type of ILD might influence the prognosis of patients
with SCLC with ILD. Sixty-three percent of exacerbation of
ILD in patients with SCLC occurred during the first-line
chemotherapy, and they could not receive subsequent che-
motherapy. On the other hand, approximately 70% of exac-
erbation of ILD in patients with NSCLC occurred during the
second or subsequent line of chemotherapy and completed
first-line chemotherapy. Thus, the rate of failure in first-line
chemotherapy might contribute to poor prognosis in SCLC.
A major limitation of this retrospective analysis was
that the diagnosis of ILD was based on CT findings and not
on histologic diagnosis. In addition, the diagnosis of exacer-
bation of ILD was also based on CT findings, and we could
not confirm histologically the exacerbation of ILD. Although
we tried to exclude infection by bacteriological examination
TABLE 4. Univariate Analysis of Risk Factors Associated with
Cytotoxic Chemotherapy-Related Exacerbation of ILD
No. of Patients
pOverall
Ex of
ILD
Non-Ex
of ILD
No. of patients 109 24 85
Gender —
Male 103 24 79
Female 6 0 6
Age (yr) 0.0897
70 56 16 40
70 53 8 45
ECOG-PS 0.7043
0–1 94 20 74
2–3 15 4 11
Histology 0.7119
NSCLC 76 16 60
SCLC 33 8 25
CT pattern 0.0054
UIP 69 21 48
Non-UIP 40 3 37
Stage 0.3186
IIIA and B 44 7 37
IV 57 14 43
Recurrence after surgical
resection
8 3 5
UIP, usual interstitial pneumonia; Ex, exacerbation; ILD, interstitial lung disease;
PS, performance status; NSCLC, non-small cell lung cancer; SCLC, small cell lung
cancer; CT, computed tomography; ECOG, Eastern Cooperative Oncology Group.
TABLE 5. Multivariate Analysis of Risk Factors Associated
with Cytotoxic Chemotherapy-Related Exacerbation of ILD
Variable Odds Ratio 95% CI p
Age (70 yr) 2.75 1.03–7.93 0.0495
ECOG-PS (2 and 3) 2.20 0.51–8.74 0.2653
CT pattern (UIP) 6.98 2.04–33.79 0.0053
PS, performance status; CT, computed tomography; UIP, usual interstitial pneu-
monia; ECOG, Eastern Cooperative Oncology Group.
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and heart failure by physical examination or echocardiogra-
phy, we cannot completely exclude pulmonary infection,
pulmonary embolism, or heart failure. Nevertheless, their
clinical and radiological courses were consistent with exac-
erbation of ILD. It was reported that in clinical practice,
surgical lung biopsies were performed in 8 to 12% of pa-
tients,20 and the ATS/ERS consensus statement also de-
scribed criteria for the clinical diagnosis of IPF.7 Moreover,
the ability of high-resolution computed tomography scanning
to diagnose IPF has reported sensitivities of 43 to 78% and
specificities of 90 to 97% for confident radiological diagno-
sis.21–25 Thus, we consider that it is appropriate to diagnose
IPF using the clinical and radiological findings in clinical
practice. Further studies are needed to clarify the relationship
between the radiological patterns and pathological patterns of
ILD for patients with lung cancer.
In conclusion, our study indicated that in patients with
lung cancer with UIP pattern on CT findings, the risk of
exacerbation of ILD was significantly higher than in those
with non-UIP pattern. In particular, greater care is required
when administering cytotoxic chemotherapy agents for pa-
tients with lung cancer with UIP pattern on CT findings.
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